167215-63-6Relevant articles and documents
QUINAZOLINONE DERIVATIVES HAVING B-RAF INHIBITORY ACTIVITY
-
Page/Page column 12, (2009/07/17)
The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
A generic building block for C- and N-terminal protein-labeling and protein-immobilization
Watzke, Anja,Gutierrez-Rodriguez, Marta,Koehn, Maja,Wacker, Ron,Schroeder, Hendrik,Breinbauer, Rolf,Kuhlmann, Juergen,Alexandrov, Kirill,Niemeyer, Christof M.,Goody, Roger S.,Waldmann, Herbert
, p. 6288 - 6306 (2007/10/03)
Expressed protein ligation (EPL) and bioconjugation based on the maleimide group (MIC-conjugation) provide powerful tools for protein modification. In the light of the importance of site-selectively modified proteins for the study of protein function, a f
Tc-99m-labeled fibrinogen receptor antagonists: Design and synthesis of cyclic RGD peptides for the detection of thrombi
Harris, Thomas D.,Rajopadhye, Milind,Damphousse, Paul R.,Glowacka, Danuta,Yu, Karmine,Bourque, Jeffrey P.,Barrett, John A.,Damphousse, David J.,Heminway, Stuart J.,Lazewatsky, Joel,Mazaika, Theresa,Carroll, Timothy R.
, p. 1741 - 1746 (2007/10/03)
Tc-99m labeled derivatives of N-Me-Arg-Gly-Asp containing cyclic peptide GP IIb/IIIa receptor antagonists are potential radiopharmaceuticals for the diagnosis of thrombosis. The design and synthesis of these peptides are described. These compounds are incorporated in rapidly growing thrombi under both arterial and venous conditions in canine models. Thrombi are clearly visible in images acquired at 50 min.
